KIDS

In the past six months, OrthoPediatrics Corp.'s stock price has been impacted by several events. The company reported record total annual revenue of $236.3 million for full year 2025, up 15% from 2024, and Q4 2025 revenue of $61.6 million, up 17% year-over-year. OrthoPediatrics reported strong Q1 2026 results with revenue of $59.4 million, up 13% year-over-year, beating estimates, and raised its full-year 2026 revenue outlook to a range of $263.0 million to $267.0 million. Throughout this period, analysts have maintained a predominantly positive sentiment. In the past three months, OrthoPediatrics insiders have sold more company stock than they have bought, with sales totaling $1,003,450.00. The share price as of May 1, 2026, was $15.63, representing a decline of 25.85% from $21.08 on May 5, 2025.